ViTRAP

ViTRAP
Virus Targeting Recombinant Agent Platform
for Infectious Diseases

Targeting Unmet Needs for Patients with Viral Diseases

Significant unmet needs exist for patients suffering from viral diseases. A new disease of viral origin, Covid-19, has impacted patients on a global scale and there is a lack of therapeutic options. However, even patients suffering from many existing viral diseases (such as Human Immunodeficiency Virus, Hepatitis B Virus, Respiratory Syncytial Virus etc.) still do not have adequate therapeutic options. That is where PineTree Therapeutics comes in with its ViTRAP technology.

OUR SOLUTION

ViTRAP is a unique, broad spectrum, antiviral technology which can design discrete, disease-specific, biologic therapeutics for many diseases with unmet needs on a global basis.

Our areas of focus:

Therapeutic Areas such as Respiratory, GI, Ocular, Liver, Genitourinary/ Sexually Transmitted Diseases, Nervous system etc.
Market Segments such as Pediatric, Women’s Health, Rare Diseases, Acute Care settings etc.
Pandemic Preparedness: Chikungunya, Lassa, Zika and other Emerging Infectious Diseases

Moreover, ViTRAP therapeutics have demonstrated to be mutation/variant-agnostic, binding strongly to the four variants (US, UK, Brazilian and South African) of Covid-19.